After months of development and feedback from customers, DrugPatentWatch is proud to announce the availability of two new datasets: Bulk […]
New features from DrugPatentWatch – Bulk API sources and clinical trials Read Post »
This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Biotech in Countries Starting with “I” – Part 11: Italy (secondo) Read Post »
The latest on what the Trump presidency means for health care, hospitals, drug companies, and medical research. Tuesday, Nov. 15
Trump in 30 seconds: Science and medicine in flux Read Post »
The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries
Which drug makers do a good job getting poor patients access to their medicines? Read Post »
To date, the Patent Trial and Appeal Board has reached a final decision in eight instituted inter partes review (IPR)
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you
Americans say lowering drug costs is a top priority Read Post »
This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below.
Addressing the Challenges of Pharmaceutical Distribution in International Markets Read Post »
By Devon Herrick / NCPA House Minority Leader Nancy Pelosi actually agrees on one thing with Speaker Paul Ryan and
How to get new drugs to consumers faster and affordably Read Post »
A new Cuban lung cancer vaccine is coming to the United States, the Roswell Park Cancer Center announced Wednesday. The
A Cuban Lung Cancer Vaccine Makes History In the U.S. Read Post »
Get new actionable insights and updates from BiotechBlog
